+29.7%
EXC vs MRNA
+153.9%
-124.2%
-18.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.6% | -2.2% | +2.8% | +0.6% |
| 7D | -1.2% | -12.7% | +11.5% | -1.3% |
| 30D | +6.2% | -20.7% | +26.8% | +6.0% |
| 3M | +2.4% | +46.3% | -43.9% | +2.6% |
| 6M | +3.8% | +305.2% | -301.5% | +5.5% |
| YTD | +7.7% | +561.2% | -553.5% | +10.6% |
| 1Y | +3.4% | +772.1% | -768.7% | +6.8% |
| 3Y | +29.7% | +147.0% | -117.2% | +35.6% |
| All | +29.7% | +153.9% | -124.2% | +35.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling